Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talacotuzumab plus Decitabine vs Decitabine in AML
NCT02472145Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2015
- Primary completion
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of talacotuzumab in acute myeloid leukemia (AML), sponsored by Janssen Pharmaceutical. Started Aug 2015; status: completed.
02
Drugs
talacotuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02472145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472145.